0001415889-23-002939.txt : 20230221
0001415889-23-002939.hdr.sgml : 20230221
20230221180616
ACCESSION NUMBER: 0001415889-23-002939
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230216
FILED AS OF DATE: 20230221
DATE AS OF CHANGE: 20230221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GONZALEZ RICHARD A
CENTRAL INDEX KEY: 0001239127
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35565
FILM NUMBER: 23649842
MAIL ADDRESS:
STREET 1: 1 N. WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbbVie Inc.
CENTRAL INDEX KEY: 0001551152
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320375147
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
BUSINESS PHONE: (847) 932-7900
MAIL ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
4
1
form4-02212023_110253.xml
X0306
4
2023-02-16
0001551152
AbbVie Inc.
ABBV
0001239127
GONZALEZ RICHARD A
1 N. WAUKEGAN ROAD
NORTH CHICAGO
IL
60064
true
true
false
false
CHAIRMAN OF THE BOARD AND CEO
Common Stock, $0.01 par value
2023-02-16
4
A
0
149732
0
A
652985
D
Common Stock, $0.01 par value
2023-02-16
4
A
0
34937
0
A
687922
D
Common Stock, $0.01 par value
2023-02-16
4
A
0
39022
0
A
726944
D
Common Stock, $0.01 par value
2023-02-16
4
A
0
33210
0
A
760154
D
Common Stock, $0.01 par value
17615
I
By Spouse
Common Stock, $0.01 par value
5900
I
By Step-daughter
Common Stock, $0.01 par value
5900
I
By Step-son
Option (Right to Buy)
149.62
2023-02-16
4
A
0
114787
0
A
2024-02-16
2033-02-15
Common Stock
114787
114787
D
Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
The reporting person disclaims beneficial ownership of these securities.
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,263 on February 16, 2024, 38,262 on February 16, 2025, and 38,262 on February 16, 2026.
Steven L. Scrogham, attorney-in-fact for Richard A. Gonzalez
2023-02-21